SCHEMBL6888864

SCHEMBL6888864

COC(=O)[C@H](Cc1ccc(Nc2nc3ccccc3n2C)cc1)Nc1c(N2C(C)CCC2C)c(=O)c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
DRD2 P14416 1/20 0.39
TBXA2R P21731 1/20 0.39
ELANE P08246 1/20 0.39
PDE10A Q9Y233 2/20 0.38
HDAC6 Q9UBN7 2/20 0.38
PTGS2 P35354 1/20 0.37
GAA P10253 2/20 0.36
OPRM1 P35372 1/20 0.36
OPRK1 P41145 1/20 0.36
OGFRL1 Q5TC84 1/20 0.36
NTRK1 P04629 1/20 0.36
NTRK2 Q16620 1/20 0.36
PARP1 P09874 1/20 0.36
PARP3 Q9Y6F1 1/20 0.36
IDH1 O75874 1/20 0.36
ITGB1 P05556 1/20 0.35
ITGA4 P13612 1/20 0.35
RPS6KA2 Q15349 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6888867 1.00 NPC1 (0.43) NPC1RAB9ADRD2TBXA2RELANE
SCHEMBL7049320 0.90 NPC1 (0.39) NPC1RAB9ADRD2TBXA2RELANE
SCHEMBL7049316 0.90 NPC1 (0.39) NPC1RAB9ADRD2TBXA2RELANE
SCHEMBL6888873 0.82 ITGB1 (0.43) HDAC6OPRM1OPRK1OGFRL1ITGB1
SCHEMBL6888872 0.82 ITGB1 (0.43) HDAC6OPRM1OPRK1OGFRL1ITGB1
SCHEMBL6884435 0.81 NPC1 (0.42) NPC1RAB9ADRD2TBXA2RELANE
SCHEMBL7718440 0.77 MAPT (0.34) ELANEPTGS2GAAITGB1ITGA4
SCHEMBL7718435 0.77 MAPT (0.34) ELANEPTGS2GAAITGB1ITGA4
SCHEMBL6887783 0.77 ELANE (0.42) NPC1RAB9ADRD2TBXA2RELANE
SCHEMBL7716455 0.76 ITGB1 (0.35) PTGS2ITGB1ITGA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6740654-B2 INHIBIT THE BINDING OF INTEGRINS TO THEIR LIGANDS AND ARE OF USE IN THE PROPHYLAXIS AND TREATMENT OF IMMUNE OR INFLAMMATORY DISORDERS, OR DISORDERS INVOLVING THE INAPPROPRIATE GROWTH OR MIGRATION OF CELLS. CELLTECH R & D LIMITED (GB) 2004-05-25 US disclosed
US-20020107263-A1 Squaric acid derivatives CELLTECH R&D, LTD. (GB) 2002-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107263-A1 Squaric acid derivatives SUCNR1, ICAM1, VCAM1 NPC1 1140/4885RAB9A 1901/4885DRD2 3645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.